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Abstract
Public health related decisions often have to balance the cost of intervention strategies with
the benefit of the reduction in disease burden. While the cost can often be inferred, forward
modelling of the effect of different intervention options is complicated and disease specific.
Here we introduce a package that is aimed to simplify this process. The package allows one
to infer parameters using a Bayesian approach, perform forward modelling of the likely
results of the proposed intervention and finally perform cost effectiveness analysis of the
results. The package is based on a method previously used in the United Kingdom to inform
vaccination strategies for influenza, with extensions to make it easily adaptable to other dis-
eases and data sources.
This is a PLOS Computational Biology Software paper.
Introduction
In-depth cost effectiveness analysis of disease intervention strategies has been difficult to
perform due to a variety of reasons, including the inherent complexity of disease dynamics,
lack of data and difficulty in predicting the success of the proposed interventions. Currently
available tools for analysing epidemiological data mainly focus on statistical analyses and
simple regression models [1–3], which is not sufficient to model the population wide effects
of proposed interventions, which include both direct and indirect effects. The exception
here is amei, an R package for optimising vaccination strategies in using an adaptive man-
agement framework while evaluating costs of an underlying stochastic epidemiological
model [4], but this package mainly relies on the use of a single (high quality) source of infor-
mation. Synthesising information from different sources of data and performing a detailed
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cost effectiveness analysis of control strategies is not supported by the currently available
packages.
In an effort to fill this gap and make sophisticated cost effectiveness analysis methods
more accessible and standardised we have developed an R package that simplifies the process.
Focusing on influenza, we present a package that offers detailed cost effectiveness analyses of
intervention strategies in a Bayesian inference framework that applies evidence synthesis tech-
niques to combine the available evidence from multiple data sources that can be stratified by
age and risk status and combined with age-stratified mixing patterns. The implementation is
based on a Susceptible Exposed Infectious Removed (SEIR) model previously developed for
pandemic influenza [5] and later used for assessing the cost/benefit of changes in the seasonal
influenza vaccine programme in the United Kingdom, and adapted to make it more generally
applicable to other settings [6, 7].
The package is particularly suitable for modelling and evaluating intervention strategies for
directly transmissible diseases that use proxy data for incidence, such as influenza-like-illness
(ILI) counts for influenza and respiratory syncytial virus (RSV). The package deals with the
whole pipeline, starting from re-organising users’ different data sources to standardise their
format to be compatible with the package, to modelling, Bayesian inference, analysing vaccina-
tion scenarios and cost effectiveness. Crucially, it includes a number of high level functions
that can do a particular analysis, and also provides access to the low level functions that are
needed if the user wants to adapt the analysis and tailor it to their specific needs (e.g. user-pro-
vided data may be different than the data we have accessible).
Design and implementation
Fig 1 illustrates the general workflow of the package. The package takes data on the influenza
outbreak and related data, such as contact rates and demographic structure, as its input, which
can then be organised into different age and risk groups. Given a set of parameters and consid-
ering the underlying model, we calculate the likelihood of observing these data. Given the data
and the likelihood function, the package uses an adaptive MCMC algorithm to derive the pos-
terior distribution of parameter values of the underlying epidemiological model. These poste-
rior parameter values can be used to explore alternative intervention strategies, and for the
cost-benefit analysis by using the functionalities of the forward modelling.
Data representation
Data analysed in the package need to be transformed into a standardised format. The default
input is in form of weekly data with each row representing the data for that week. Other dates
can be used when using the lower level functions provided by the package. Columns contain
the data stratified by age group. If the data are also stratified by risk group then the first group
of columns will hold the data for one risk group, stratified by age group. The next set of col-
umns will be the next risk group by age group, etc. The input as used in the examples consist
of (see Fig 1):
• Weekly ILI counts, stratified by age in separate columns.
• Weekly virological data, stratified by age in separate columns.
• Weekly vaccination data, stratified by risk group and by age as explained above.
• Population size by age.
• Contact data by age group. The example data included in the package are based on the
POLYMOD study [8].
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Functionalities
Stratifying the data. General functions are provided as part of the package to stratify
the data and convert them to a suitable formatting for model fitting (e.g stratify_by_
age(. . .)) and easily stratify the data into different user-specified age and risk groups. The
choice of age groups and risk groups is flexible and depends on the data provided and the goal
of the user. For example, for the UK the influenza occurrence data are separated into 5 age
groups, while the vaccination data are divided into 7 different age groups, so it was decided to
model 7 different age groups, but transform them into 5 before performing the fitting [6].
Vaccination scenarios. The package defines vaccination scenarios as a combination of
the effectiveness of the vaccine against the dominant strain and the coverage over time. The
effectiveness of the influenza vaccine is highly dependent on the match between the vaccine
strain and the dominant strain circulating in the population. Influenza vaccine effectiveness
is also age dependent, with the vaccine generally being less effective for the older age groups
(e.g. because of immunosenescence). Vaccine coverage is determined by the vaccination pro-
gramme. In most countries influenza vaccination is aimed at individuals aged 65 years and
Fig 1. Workflow for the fluEvidenceSynthesis package.
https://doi.org/10.1371/journal.pcbi.1005838.g001
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above, and at the high risk groups. In the United States and, more recently, in the UK the sea-
sonal influenza vaccination programme was extended to include healthy children [7, 9]. The
period during which the vaccination programme is carried out is also country-dependent. In
the UK vaccination starts in October and runs until the end of January, with the largest uptake
rate during the first month. The function as.vaccination.calendar(. . .) takes the
effectiveness and coverage by age and risk groups and the dates at which the coverage data
were measured to construct a calendar as used in the epidemiological model.
Epidemiological model. The epidemiological model implemented in the package is an
SEIR model, with two compartments for the Exposed and Infectious states that result in a
more realistic gamma distributed average time for both the Exposed and Infectious states
(rather than an exponentially distributed waiting time with single E and I compartments). The
general model has the following form:
dSik
dt
¼   liSik
dE1ik
dt
¼ liSik   g1E1ik
dE2ik
dt
¼ g1 ðE1ik   E
2
ikÞ
dI1ik
dt
¼ g1E2ik   g2I
1
ik
dI2ik
dt
¼ g2 ðI1ik   I
2
ikÞ
dRik
dt
¼ g2I2ik
ð1Þ
where Sik is the number of susceptibles in the age group i and risk group k, E1ik and E
2
ik are two
compartments with exposed but not yet infectious individuals of age group i and risk group
k, I1ik and I
2
ik represent infectious individuals, and immune individuals of age group i and risk
group k are given by Rik. The overall rate of loss of latency and infectiousness are respectively
given by γ1/2 and γ2/2, while the age-group-specific force of infection λi is given by
li ¼ si
Xx
j¼1
Xy
k¼1
bi;j ðI
1
jk þ I
2
jkÞ ð2Þ
where βi,j is the effective contact rate between individuals in age group i and age group j, and σi
is the susceptibility of the age group i (that can be inferred from serological data) and x and y
are the total number of age groups and risk groups, respectively. The effective contact rate is
the transmission rate (Λ) multiplied with the probability of a contact between a individual in
age group i and one in age group j (Ci,j).
Eq 1 defines the trajectory of the infection for each age and risk group. To implement vacci-
nation in the package we further separate each of the epidemiological compartments (SEEIIR)
in the model (1) into vaccinated and non-vaccinated groups. Non-vaccinated people of age i
and risk k are vaccinated at a given rate (μik) regardless of their epidemiological status. If the
subject has already been exposed or infected, the infection progresses as normal. Depending
on the efficacy of the vaccine (αi), a proportion of vaccinated susceptibles will become immune
(μikαiSik) and the total daily rate with which susceptible individuals become vaccinated and
recovered is μik(Rik + αiSik). If the vaccine is not 100% effective a proportion of vaccinated
fluEvidenceSynthesis: An R package for epidemiological outbreaks
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individuals will become ‘vaccinated susceptibles’ (μik(1 − αi)Sik). For full details of the underly-
ing model see the supplementary information of [6].
Inference. In addition to the numerically optimised epidemiological model we also imple-
mented a highly optimised likelihood function. The basic likelihood function incorporated in
the package has the following form for each age group (i):
Lðnþi ; ni;miji;c; yiÞ ¼
X
mþi
Lðnþi ; ni;mijm
þ
i ; yiÞLðm
þ
i ;miji;c; yiÞ
The likelihood of the data, given the ODE model, is separated into two parts. First, we assume
that the virologically tested sera (ni) are a subsample of the people identified with an influenza-
like-illness. As such, the number tested positive (nþi ) is distributed as a hypergeometric func-
tion, with the number of people tested (ni), the number of people actually with that strain of
influenza (mþi ) and the total number of people (mi). The second part of the likelihood function
defines how the values mþi and mi depend on the ascertainment probability (i), external inflow
of influenza (ψ) and the epidemiological model parameters (θi = {Λ, σi, I0}, with I0 the log
transformed initial infected population: I0 ¼ log I1i ð0Þ). Here, subscript i designates the age
group i and the parameters (i; ψ; Λ; σi; I0) are inferred from the data. We have no direct data
for the number of people with a particular strain of influenza (mþi ) so we integrate over all pos-
sibilities, resulting in a computationally intensive calculation. For full details of the likelihood
and the method of optimisation see [6].
Finally, an advanced MCMC algorithm is used to generate samples from the posterior dis-
tribution of the parameter values using this likelihood function [[10]; Algorithm 6B].
The use of the hypergeometric distribution and the resulting computational complexity of
the likelihood function above is due to the fact that the source of data on influenza incidence is
dual, composed of the ILI data, which is an umbrella for several respiratory infections and
virology testing which indicates which of these diseases is circulating. The actual incidence of
one particular pathogen can thus only be inferred by combining these two sources. When
direct data on disease prevalence are available the fluEvidenceSynthesis package can
still be used, by replacing the above likelihood function with a simplified likelihood function.
The vignettes of the package provide in-depth information on how to replace the likelihood
function, with a user-specified function.
Forward modelling. The resulting posterior samples of the parameters can be used to
model alternative interventions and explore the changes in the resulting outbreak size. This is
generally done by adapting the previously fitted epidemiological model to account for the new
intervention strategy. This model is then run using the posterior parameter samples and the
final disease burden can be compared under the current scenario and/or under alternative sce-
narios. The disease burden can also be used to calculate the cost and benefits of the alternative
scenarios.
Cost effectiveness. The package provides a number of functions to aid with calculating
the cost effectiveness. Based on existing mortality rate and data on hospitalised cases, the inci-
dence number is transformed into the number of consultations, hospitalisations and deaths
using the function public_health_outcome(.. .). These numbers can then be con-
verted into the costs and the benefits in reduced consultations, hospitalisations and mortality
due to alternative intervention methods. It is also possible to calculate the number of vaccine
doses needed using the vaccine_doses(. . .) function. Some of the rates and associated
costs are country-specific as they depend on the healthcare system and therefore not included
in the package.
fluEvidenceSynthesis: An R package for epidemiological outbreaks
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Results
We present an example examining the potential outbreak size reduction by extending the sea-
sonal vaccination programme to include increased coverage in children aged 5-14 years. In
this example we explore scenarios where either 40% or 80% coverage is achieved in the 5-14
year olds.
Following the workflow laid out in Fig 1 we can divide the needed process as follows:
1. Collect data for each season and subtype
The data available depends on the study area and collection agency, so this step is variable.
Examples of the needed layout using UK data are provided with the package and can be used
to base your data format on.
2. Run inference (for each season and subtype)
Performing the default parameter inference implemented in this package (see [6]) using
user-specified data is straightforward by running the analysis using the inference(. . .)
function, that needs to be run for each season and strain (as illustrated in the R (pseudo)code
example below). Note that for performance reasons it is advised to adapt this pseudocode to
run in parallel for each season and strain.
The inference(. . .) function is a high level function that implements the whole infer-
ence part of the workflow. This function takes all the data (as described earlier in this manu-
script) and returns posterior samples of the parameters. The documentation of the package
also shows how to adapt parts of the inference function for use with a different underlying epi-
demiological model, or different likelihood function. Fig 2 highlights the difference between
our prior distribution of R0 and the posterior distribution of R0 following parameter inference.
In the 2007/08 season the posterior is very similar to the prior. This is probably because in that
season the incidence of H3N2 was very low compared to the other two seasons shown here.
3. Forward modelling
• Define alternative scenario
Any vaccination scenario depends on the efficacy of the vaccine, the total vaccine uptake,
and the relative rate of uptake over time (e.g. during the first month the uptake rate in the UK
is higher than in later months). To model our scenario we scaled the total uptake rate to 40%
and 80%, while keeping the other factors constant. This was achieved by calculating the total
inference.results <- list()
for (season in seasons) {
for (subtype in subtypes) {
inference.results[[season]][[subtype]] <-
inference(demography[[season]], ili[[season]]
[[subtype]], . . .)
}
}
fluEvidenceSynthesis: An R package for epidemiological outbreaks
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uptake rate for the relevant age group (i.e. V =
R
v(t)dt) and scaling up the original uptake rate
to result in a total coverage of Vs = 0.4 or Vs = 0.8 (i.e. v^ðtÞ ¼ VsvðtÞV).
• Run vaccination scenario for all results with old vs. new scenario
The inference step results in a number of posterior samples for the parameters and contact
data. We can now use these samples and model the outcome of our alternative vaccination sce-
nario. Then we calculate the difference in influenza burden between the original and our alterna-
tive vaccination scenarios. This is done by taking samples from each season and strain combina-
tion and calculating the disease burden over all the seasons/strains of the new scenario relative to
the original scenario (using the vaccination_scenario(. . .) function). The results are
summarized in Fig 3, showing a reduction of influenza cases in both the low and high risk groups
under the new scenario. The magnitude of the reduction is dependent on the level of vaccine
coverage. The higher coverage (80%) results in a reduction of around 5.9 million, while lower
coverage (40%) results in a reduction of influenza cases of approximately 3.5 million (Fig 3).
4. Cost effectiveness
Performing the cost effectiveness analysis requires calculating the costs and benefits of the
proposed intervention. The main cost in increasing vaccination stems from administering
Fig 2. Posterior and prior probability of R0 for different seasons and serotype H3N2.
https://doi.org/10.1371/journal.pcbi.1005838.g002
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additional vaccine doses, which can be calculated with the vaccine_doses(. . .) function.
Resulting benefits will mostly come from associated decreases in the number of consultations,
reduced hospital admissions and finally reduced mortality. Generally, these values are calcu-
lated as the proportion of influenza cases that result in consultations, hospital admissions etc.
The pseudocode below shows how to calculate the cost associated with a new vaccine calendar,
assuming that 7% of infected people visit the GP and 0.2% and 2% of infected individuals are
hospitalised for the low risk and high risk groups respectively.
Fig 3. Reduction in influenza incidence under increased vaccination of the age group between 5 and
15. The orange colour signifies the reduction in patients classified as high risk. The blue colour is the reduction
in the low risk population. The first results correspond to a scenario where 40 percent coverage is achieved,
the second to a coverage of 80.
https://doi.org/10.1371/journal.pcbi.1005838.g003
posterior_cost <- rep(0, nbatch)
for (season in seasons) {
# Vaccine price covers all subtypes
posterior_cost <- posterior_cost +
rep(vaccine_price
(vaccine doses(proposed_calender) - vaccine doses
(calendar)), nbatch)
fluEvidenceSynthesis: An R package for epidemiological outbreaks
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Another important aspect of cost effectiveness calculations is the reduction of mortality due
to incidence reduction. Fig 4 shows the cost of different vaccination scenarios as a function of
reduction in mortality. More sophisticated cost effectiveness analysis could also take into
account the risk and cost of hospitalisation as well as indirect effects due to increased vaccine-
induced immunity in the population.
Availability and future directions
The R package we presented here was developed to make advanced analysis of disease dynam-
ics more approachable for data analysts and scientists interested in public health related ques-
tions. The package implemented the whole process of preparing the data, running the model,
inferring posterior parameter distributions and performing cost effectiveness analysis. The
approach implemented is based on the method by [6] and [7]. The package is modular in
design, such that the method can be adapted by, for example, changing the underlying epide-
miological model and/or likelihood function. While advanced methods such as implemented
in this package are inherently complex and traditionally applied by specialised researchers, the
package is designed to make the analysis accessible to a wider group of researchers. The pack-
age is freely available under the GPL-3.0 license on github at https://github.com/MJomaba/flu-
evidence-synthesis.
for (subtype in subtypes) {
# Calculate incidence of different outcomes
outcomes <- rowSums(public health outcome(
list(00gp00 = 0:07, 00hospital00 = c(0:002, 0:02)),
vaccination scenario(vaccine calendar ¼ calendar,
. . .), . . .))
# Calculate incidence of different outcomes under proposed policy
new_outc <- rowSums(public health outcome(
list(00gp00 = 0:07, 00hospital00 = c(0:002, 0:02)),
vaccination scenario(vaccine calendar ¼ proposed_
calendar, . . .), . . .))
# Difference of cost under new intervention versus existing policy
posterior_cost <- posterior_cost +
gp_cost(new_outc$gp - outcomes$gp) +
hospital_cost(new_outc$hospital - outcomes$hospital)
}
}
posterior_cost <- posterior_cost/length(seasons) # Per season
fluEvidenceSynthesis: An R package for epidemiological outbreaks
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Contact matrix
Currently no explicit model of contact rates is included and inference of the contact matrix is
performed by bootstrapping the available contact data [6]. One model we are working on is to
use demographic data to inform contact inference, similar to the approach explored by [11].
Another simplification in the current approach is the assumption that the contact matrix is
constant throughout the season. Indeed, contact matrices are dependent on behaviour and this
can change during the year [12], either due to external drivers (e.g. school vacation) or in
response to influenza (e.g. staying at home when sick [13]). These changes in behaviour could
then be incorporated into the contact model. Due to the modularity of the package it is possi-
ble to plug-in such a contact model and explore its effect on intervention strategies.
Multi-year
The package simulates each strain and season independently. An interesting possible addition
would be to implement multi-year models, i.e. models where the current state is influenced by
the previous years results. One possible approach would be to use the posterior of the previous
season as a prior for the next season, but that would not capture dynamic effects of alternative
Fig 4. Cost effectiveness analysis showing the vaccine cost by reduction in mortality under two
vaccination scenarios, taking into account uncertainty in vaccine cost, influenza incidence and death
risk. The colours represent the uncertainty around the different scenarios. The lines represent two potential
thresholds: (1) for a cost of up to 1000 for each life saved both programmes are not cost effective, (2) for a
cost up to 10,000 per life saved both programmes are likely to be cost effective. The parameter values used in
this figure (cost of vaccine: 17 ± 2.5 and mortality risk: 0.0025 ± 0.0005) were chosen for illustrative purposes
only and should not be taken as realistic values.
https://doi.org/10.1371/journal.pcbi.1005838.g004
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vaccination strategies. Capturing long-term dynamic effects requires an explicit multi-year
epidemiological model, which introduces challenges of modelling antigenic evolution of anti-
genic strains as well as waning of immunity [14–16]. Such a model would need to be calibrated
jointly to multiple sources of data (e.g. DNA sequences, syndromic surveillance, serology,
demography) [17].
Beyond influenza
The package has been developed with a focus on influenza data, but could potentially be
adapted to predict the impact and cost effectiveness for a range of interventions for other infec-
tious diseases. The parts that are disease specific are the likelihood function and the transmis-
sion model. The transmission model is an SEIR model which can be used to capture a wide
variety of diseases. If this model is not suitable for your analysis then it is of course possible to
replace it with another model while still using the other parts of the package.
The likelihood function is suitable for any disease where most of the data on disease occur-
rence is a proxy for the actual occurrence, augmented with a smaller source of direct data
(virological). If more direct data are available then it might be appropriate to replace the cur-
rent likelihood function with a (simplified) likelihood that is only based on the direct data.
Conclusion
The fluEvidenceSynthesis package implements the needed pipeline to go from raw
epidemiological data to a cost effectiveness analysis based on Bayesian inference methods. The
workflow implemented is based on the analysis used to predict the cost effectiveness of paedi-
atric vaccination in the UK [6,7]. The package itself has been successfully used in further analy-
ses, most notably [18] and [19]. Feedback from those analyses has been used to improve the
package. It is implemented as a series of loosely connected steps and allows the researcher to
replace any of these phases with their own method.
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